| scholarly article | Q13442814 |
| P50 | author | Pascal Poignard | Q72530329 |
| Linda-Gail Bekker | Q30001903 | ||
| Walter Jaoko | Q37383427 | ||
| Dennis R. Burton | Q56331320 | ||
| Etienne Karita | Q72386151 | ||
| P2093 | author name string | Robert Paris | |
| Punnee Pitisuttithum | |||
| Anton Pozniak | |||
| Laura M Walker | |||
| Wayne C Koff | |||
| Tony Tarragona-Fiol | |||
| Patricia E Fast | |||
| André Inwoley | |||
| Jack Dehovitz | |||
| Terri Wrin | |||
| Josephine Birungi | |||
| Olivier Manigart | |||
| Dagna S Laufer | |||
| Dale A McPhee | |||
| Emily Carrow | |||
| Frances H Priddy | |||
| George Miiro | |||
| Jennifer K Lehrman | |||
| Mark Boaz | |||
| Melissa D Simek | |||
| Pham Pung | |||
| Wasima Rida | |||
| P2860 | cites work | A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals | Q24560010 |
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS | Q28262859 | ||
| Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion | Q73959618 | ||
| An AIDS vaccine: no time to give up | Q81065143 | ||
| [Neutralizing antibodies in hepatitis C virus infection] | Q81242400 | ||
| HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. | Q30369945 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity | Q33782556 | ||
| Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. | Q33786382 | ||
| Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies | Q33804540 | ||
| Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge | Q33852768 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines | Q33911935 | ||
| Development of hepatitis C virus vaccines: challenges and progress. | Q34254941 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D | Q34323863 | ||
| Summary of Antibody Workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases | Q34438597 | ||
| Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. | Q34575508 | ||
| Neutralizing antibodies against HIV -- back in the major leagues? | Q34712716 | ||
| Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques | Q35101333 | ||
| Defining the Protective Antibody Response for HIV-1 | Q35109054 | ||
| Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. | Q35849408 | ||
| A vaccine for HIV type 1: The antibody perspective | Q36037760 | ||
| Human antibodies from combinatorial libraries. | Q36717602 | ||
| Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. | Q36974754 | ||
| Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies | Q37033269 | ||
| Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
| Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels | Q37106916 | ||
| Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins | Q37742938 | ||
| Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico | Q38964288 | ||
| Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma | Q39092746 | ||
| Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum | Q40538332 | ||
| Antibody-based HIV-1 vaccines: recent developments and future directions | Q42738983 | ||
| Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge | Q43048336 | ||
| Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. | Q43872744 | ||
| HIV-1: nature's master of disguise | Q44031352 | ||
| Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. | Q45729198 | ||
| Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates | Q45763324 | ||
| Lymphadenopathy associated virus in AIDS, lymphadenopathy associated syndrome, and classic Kaposi patients in Greece | Q45806090 | ||
| HIV vaccine design and the neutralizing antibody problem | Q46474020 | ||
| Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? | Q52940647 | ||
| Vaccination against the major infectious diseases | Q53532099 | ||
| Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. | Q55041754 | ||
| Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons | Q56459658 | ||
| Age‐Dependent Differences in IgG Isotype and Avidity Induced by Measles Vaccine Received during the First Year of Life | Q58218799 | ||
| Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120 | Q72067428 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| P304 | page(s) | 7337-7348 | |
| P577 | publication date | 2009-05-13 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | |
| P478 | volume | 83 |
| Q28730532 | 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity |
| Q35081119 | 9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles |
| Q36294739 | A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses |
| Q26829865 | A Blueprint for HIV Vaccine Discovery |
| Q41819464 | A Novel Rabbit Monoclonal Antibody Platform To Dissect the Diverse Repertoire of Antibody Epitopes for HIV-1 Env Immunogen Design |
| Q40606158 | A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. |
| Q26851165 | A brief history of the global effort to develop a preventive HIV vaccine |
| Q100755368 | A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch |
| Q35783015 | A critical question for HIV vaccine development: which antibodies to induce? |
| Q34047445 | A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals |
| Q35076748 | A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component |
| Q90066250 | A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants |
| Q44561674 | A pilot study on an attenuated Chinese EIAV vaccine inducing broadly neutralizing antibodies |
| Q35760446 | A single amino acid deletion in the matrix protein of porcine reproductive and respiratory syndrome virus confers resistance to a polyclonal swine antibody with broadly neutralizing activity |
| Q52584556 | A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection |
| Q85389317 | A sweet surprise for HIV broadly neutralizing antibodies |
| Q35883727 | Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire |
| Q40340474 | Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding |
| Q59056415 | Accelerating HIV vaccine development |
| Q38110775 | Accelerating Next-Generation Vaccine Development for Global Disease Prevention |
| Q35077704 | Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic |
| Q38196689 | Adeno-associated virus delivery of broadly neutralizing antibodies |
| Q27684503 | Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains |
| Q37728775 | An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability |
| Q59351009 | An HIV-1 broadly neutralizing antibody from a clade C infected pediatric elite neutralizer potently neutralizes the contemporaneous and autologous evolving viruses |
| Q91473474 | An MPER antibody neutralizes HIV-1 using germline features shared among donors |
| Q37680009 | An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. |
| Q35382871 | Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors |
| Q64061234 | Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens |
| Q26774672 | Anergic B Cells: Precarious On-Call Warriors at the Nexus of Autoimmunity and False-Flagged Pathogens |
| Q35641369 | Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency |
| Q39108744 | Anti-retroviral antibody FcγR-mediated effector functions |
| Q27011574 | Antibodies in HIV-1 vaccine development and therapy |
| Q33786443 | Antibody 10-1074 suppresses viremia in HIV-1-infected individuals |
| Q35660279 | Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization |
| Q38293417 | Antibody recognition of HIV and dengue glycoproteins |
| Q26991572 | Antibody responses to envelope glycoproteins in HIV-1 infection |
| Q92461201 | Antibody responses to viral infections: a structural perspective across three different enveloped viruses |
| Q59339950 | Antibody-mediated prevention and treatment of HIV-1 infection |
| Q36447540 | Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design |
| Q28066335 | Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies |
| Q36421569 | Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). |
| Q37010878 | Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies |
| Q36692987 | Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. |
| Q34022578 | Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination |
| Q33591736 | Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance |
| Q34008741 | B Cell Depletion in HIV-1 Subtype A Infected Ugandan Adults: Relationship to CD4 T Cell Count, Viral Load and Humoral Immune Responses |
| Q64973575 | B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques. |
| Q37171260 | B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates |
| Q34239109 | B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection |
| Q36171833 | B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. |
| Q38025633 | Basic research in HIV vaccinology is hampered by reductionist thinking |
| Q46296261 | Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials |
| Q35077716 | Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. |
| Q33955745 | Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein |
| Q33614495 | Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables |
| Q92280921 | Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope |
| Q34473958 | Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface |
| Q27675131 | Broad and potent neutralization of HIV-1 by a gp41-specific human antibody |
| Q36131738 | Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein |
| Q29615361 | Broad neutralization coverage of HIV by multiple highly potent antibodies |
| Q38707583 | Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response |
| Q91812746 | Broadly Neutralizing Antibodies against HIV: Back to Blood |
| Q40679052 | Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design |
| Q27678062 | Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans |
| Q35894094 | Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort |
| Q35077039 | Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia |
| Q39001126 | Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers |
| Q38065391 | Broadly neutralizing antibodies against HIV-1: templates for a vaccine |
| Q41353120 | Broadly neutralizing antibodies against the rapidly evolving porcine reproductive and respiratory syndrome virus |
| Q57815702 | Broadly neutralizing antibodies in HIV-1 treatment and prevention |
| Q37397841 | Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission |
| Q38811735 | Broadly neutralizing antibodies: An approach to control HIV-1 infection |
| Q56974226 | Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? |
| Q99550889 | CD4+ T Cell-Mimicking Nanoparticles Broadly Neutralize HIV-1 and Suppress Viral Replication through Autophagy |
| Q34545420 | CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors |
| Q36684710 | CXCL13 is a plasma biomarker of germinal center activity |
| Q27026806 | Catching HIV 'in the act' with 3D electron microscopy |
| Q38154038 | Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies |
| Q64982392 | Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity. |
| Q33798076 | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. |
| Q33957908 | Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco |
| Q34300812 | Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection |
| Q47095100 | Circulating Plasmablasts from Chronically Human Immunodeficiency Virus-Infected Individuals Predominantly Produce Polyreactive/Autoreactive Antibodies |
| Q35861256 | Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research |
| Q36547166 | Comparative Evaluation of HIV-1 Neutralization in External Secretions and Sera of HIV-1-Infected Women |
| Q33867353 | Comparison of Antibody Repertoires Produced by HIV-1 Infection, Other Chronic and Acute Infections, and Systemic Autoimmune Disease |
| Q34663118 | Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques |
| Q27674878 | Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies |
| Q33603702 | Comprehensive Characterization of Humoral Correlates of Human Immunodeficiency Virus 1 Superinfection Acquisition in High-risk Kenyan Women |
| Q36694111 | Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop |
| Q60951055 | Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India |
| Q36319309 | Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library |
| Q36105782 | Cross-reactive broadly neutralizing antibodies: timing is everything |
| Q27662167 | Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 |
| Q37967232 | Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV) |
| Q30397595 | Current views on the potential for development of a HIV vaccine |
| Q27684578 | Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization |
| Q36742228 | Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies |
| Q35060140 | Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system |
| Q40476608 | Determinants of HIV-1 broadly neutralizing antibody induction. |
| Q36736392 | Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques |
| Q40251478 | Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region |
| Q40047250 | Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies |
| Q37042563 | Development of prophylactic vaccines against HIV-1. |
| Q97545395 | Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus |
| Q37551245 | Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors |
| Q34034659 | Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection |
| Q46294146 | Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study |
| Q37644030 | Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. |
| Q36194234 | Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth |
| Q34594036 | Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. |
| Q33764917 | Early development of broadly neutralizing antibodies in HIV-1-infected infants |
| Q34594726 | Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection |
| Q36506821 | Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent |
| Q37036833 | Emergence of gp120 V3 Variants Confers Neutralization Resistance in an R5 Simian-Human Immunodeficiency Virus-Infected Macaque Elite Neutralizer That Targets the N332 Glycan of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein |
| Q34687653 | Emerging concepts on T follicular helper cell dynamics in HIV infection |
| Q35070898 | Engineering and exploitation of a fluorescent HIV-1 gp120 for live cell CD4 binding assays |
| Q38717198 | Engineering broadly neutralizing antibodies for HIV prevention and therapy |
| Q34533041 | Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants |
| Q35735385 | Enhanced HIV-1 neutralization by antibody heteroligation |
| Q41475637 | Env-Specific Antibodies in Chronic Infection versus in Vaccination |
| Q42959357 | Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. |
| Q34819651 | Evidence for a Continuous Drift of the HIV-1 Species towards Higher Resistance to Neutralizing Antibodies over the Course of the Epidemic |
| Q36388754 | Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape |
| Q37254327 | Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations |
| Q34478071 | Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject |
| Q47547492 | FUNCTIONAL OPTIMIZATION OF BROADLY NEUTRALIZING HIV-1 ANTIBODY 10E8 BY PROMOTING MEMBRANE INTERACTIONS. |
| Q38615357 | Fcγ receptor pathways during active and passive immunization |
| Q35491705 | Feline immunodeficiency virus (FIV) neutralization: a review |
| Q33680883 | Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions |
| Q27671696 | Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing |
| Q36634790 | Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection. |
| Q74440182 | Fresh targets give hope for HIV vaccine |
| Q38026862 | Gene therapy as a vaccine for HIV-1 |
| Q27313556 | Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy |
| Q34571277 | Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals |
| Q34392963 | Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies |
| Q35582579 | Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses |
| Q46454115 | HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage |
| Q54232567 | HIV Vaccination: A Roadmap among Advancements and Concerns. |
| Q36249933 | HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions |
| Q33703451 | HIV neutralizing antibodies: clinical correlates and implications for vaccines |
| Q37958563 | HIV vaccine development: Challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem |
| Q38210557 | HIV vaccines: a brief overview. |
| Q34342558 | HIV vaccines: lessons learned and the way forward |
| Q37851950 | HIV vaccines: progress to date. |
| Q28647225 | HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers |
| Q27022055 | HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design |
| Q57030223 | HIV-1 cell-to-cell transmission and broadly neutralizing antibodies |
| Q38665463 | HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies |
| Q37360774 | HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. |
| Q33947008 | HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 |
| Q37073506 | HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds |
| Q59811711 | HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth |
| Q34657046 | HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing |
| Q21090490 | HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response |
| Q37236504 | HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice |
| Q35096836 | HIV-1-specific antibody responses during acute and chronic HIV-1 infection |
| Q35821193 | HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation |
| Q40159913 | HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection |
| Q27000480 | HIV‐1 neutralizing antibodies: understanding nature's pathways |
| Q36766715 | Harnessing CD4+ T cell responses in HIV vaccine development |
| Q26766153 | Harnessing the protective potential of HIV-1 neutralizing antibodies |
| Q36827377 | Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock |
| Q33920519 | High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutraliz |
| Q35826509 | High-Mannose Glycan-Dependent Epitopes Are Frequently Targeted in Broad Neutralizing Antibody Responses during Human Immunodeficiency Virus Type 1 Infection |
| Q59359604 | Highly Attenuated Infection With a Vpr-Deleted Molecular Clone of Human Immunodeficiency Virus-1 |
| Q42228026 | Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy. |
| Q35836169 | Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency |
| Q40605061 | Host-Pathogen Coevolution and the Emergence of Broadly Neutralizing Antibodies in Chronic Infections |
| Q39250593 | How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design |
| Q35653703 | How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? |
| Q38618790 | How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses |
| Q39108735 | Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies |
| Q28602877 | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies |
| Q37718722 | Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses |
| Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
| Q33350161 | Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression |
| Q34407843 | Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection |
| Q30424366 | Human immunodeficiency virus vaccine trials |
| Q30234773 | Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem |
| Q39459609 | Humanized Mouse Models for Human Immunodeficiency Virus Infection. |
| Q39108796 | Identification and specificity of broadly neutralizing antibodies against HIV |
| Q88582157 | Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses |
| Q40449526 | Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. |
| Q36827300 | Identification of an HIV-1 Clade A Envelope That Exhibits Broad Antigenicity and Neutralization Sensitivity and Elicits Antibodies Targeting Three Distinct Epitopes |
| Q35057901 | IgM Repertoire Biodiversity is Reduced in HIV-1 Infection and Systemic Lupus Erythematosus |
| Q47600062 | Immune Interventions to Eliminate the HIV Reservoir |
| Q30362489 | Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? |
| Q35667479 | Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein |
| Q38219407 | Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1. |
| Q92210244 | Impact of HIV-1 Diversity on Its Sensitivity to Neutralization |
| Q34593647 | Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies |
| Q36978467 | Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy |
| Q40046407 | Improved Vaccine against PRRSV: Current Progress and Future Perspective |
| Q38009870 | Improved outlook on HIV-1 prevention and vaccine development |
| Q39113783 | Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers |
| Q41885613 | Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection |
| Q33611645 | Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy |
| Q34540645 | Induction of immunity to human immunodeficiency virus type-1 by vaccination |
| Q64085668 | Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus |
| Q37789226 | Inhibition of HIV‐1 Entry: Multiple Keys to Close the Door |
| Q40159859 | Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response |
| Q35167400 | Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies |
| Q58738833 | Large-Scale Screening of HCMV-Seropositive Blood Donors Indicates that HCMV Effectively Escapes from Antibodies by Cell-Associated Spread |
| Q33557844 | Lessons learned from human HIV vaccine trials |
| Q37910841 | Limitations to the structure‐based design of HIV‐1 vaccine immunogens |
| Q36831651 | Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization |
| Q92400606 | Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual |
| Q35826458 | Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity |
| Q64968778 | Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. |
| Q35192782 | Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 |
| Q36531018 | Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies |
| Q34023249 | Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses |
| Q36781872 | Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains |
| Q36978277 | Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure |
| Q36438523 | Most rhesus macaques infected with the CCR5-tropic SHIV AD8 generate cross-reactive antibodies that neutralize multiple HIV-1 strains |
| Q36249053 | Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially |
| Q47575476 | Moving ahead an HIV vaccine: To neutralize or not, a key HIV vaccine question |
| Q38120526 | Multiantibody strategies for HIV. |
| Q27679353 | Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies |
| Q39845890 | Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen |
| Q35864051 | N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03 |
| Q37633417 | Native-like Env trimers as a platform for HIV-1 vaccine design |
| Q37619134 | Natural infection as a blueprint for rational HIV vaccine design |
| Q91582856 | Neutralization and beyond: Antibodies and HIV-1 acquisition |
| Q47562235 | Neutralization tiers of HIV-1. |
| Q36837324 | Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark |
| Q53693698 | Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs |
| Q34550046 | Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success |
| Q33887693 | Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? |
| Q37519312 | Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? |
| Q36603515 | Neutralizing antibodies to HIV-1 induced by immunization. |
| Q36433894 | New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency |
| Q36011269 | New Paradigms for HIV/AIDS Vaccine Development |
| Q34344323 | New templates for HIV-1 antibody-based vaccine design |
| Q41924059 | Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. |
| Q50617948 | Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies |
| Q35868102 | PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. |
| Q92327047 | Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1 |
| Q30358434 | Passive immunization against HIV/AIDS by antibody gene transfer. |
| Q47548101 | Passive immunotherapy of viral infections: 'super-antibodies' enter the fray |
| Q34230556 | Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques |
| Q30402036 | Phylogenetic structure in African HIV-1 subtype C revealed by selective sequential pruning |
| Q38023086 | Plant made anti-HIV microbicides--a field of opportunity |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q42265635 | Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans |
| Q34742533 | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop |
| Q35665921 | Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1 |
| Q35124761 | Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method |
| Q33638320 | Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. |
| Q33702217 | Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection |
| Q38206519 | Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1). |
| Q57093617 | Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1 |
| Q64080897 | Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus |
| Q37785949 | Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. |
| Q39315316 | Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B′-infected former plasma donors from China naïve to antiretroviral therapy |
| Q37741310 | Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy |
| Q56970600 | Progress in HIV vaccine development |
| Q56600657 | Progress in HIV-1 vaccine development |
| Q37549777 | Progress toward active or passive HIV-1 vaccination |
| Q42215329 | Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. |
| Q38534943 | Prospects for a globally effective HIV-1 vaccine |
| Q37625877 | Protein engineering strategies for the development of viral vaccines and immunotherapeutics |
| Q37584635 | Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. |
| Q39610645 | Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4 |
| Q35973587 | Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys |
| Q35647701 | Rapid development of glycan-specific, broad, and potent anti–HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque |
| Q33725673 | Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors |
| Q42726161 | Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. |
| Q29619511 | Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 |
| Q35603504 | Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. |
| Q30235024 | Recent Insights into the HIV/AIDS Pandemic |
| Q30353580 | Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1 |
| Q58569712 | Recent progress in broadly neutralizing antibodies to HIV |
| Q34539819 | Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs |
| Q34709433 | Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex |
| Q38656764 | Regulation of Subunit-Specific Germinal Center B Cell Responses to the HIV-1 Envelope Glycoproteins by Antibody-Mediated Feedback. |
| Q34225659 | Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine |
| Q58382398 | Retroviral Pseudotypes - From Scientific Tools to Clinical Utility |
| Q36670538 | Role of IL-21 and IL-21 Receptor on B Cells in HIV Infection |
| Q38046828 | Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. |
| Q33898131 | Role of humoral immunity in host defense against HIV. |
| Q41019767 | Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults |
| Q35943521 | Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site |
| Q58598623 | Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time |
| Q34397758 | Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies |
| Q41876895 | Sequential Evolution and Escape from Neutralization of Simian Immunodeficiency Virus SIVsmE660 Clones in Rhesus Macaques |
| Q34456367 | Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China |
| Q34096530 | Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates |
| Q27677117 | Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization |
| Q36231944 | Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics |
| Q43454270 | Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection |
| Q30385813 | Status of vaccine research and development of vaccines for HIV-1. |
| Q36559665 | Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120 |
| Q57093739 | Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies |
| Q37123501 | Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers |
| Q27683553 | Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers |
| Q38050485 | Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. |
| Q26829461 | Structural insights on the role of antibodies in HIV-1 vaccine and therapy |
| Q27662155 | Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 |
| Q37409244 | Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site |
| Q34987048 | Structure-based Vaccine Design in HIV: Blind Men and the Elephant? |
| Q35196671 | Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design |
| Q41835711 | Synthesis of multivalent glycopeptide conjugates that mimic an HIV epitope |
| Q52657148 | T Cell Subsets in the Germinal Center: Lessons from the Macaque Model |
| Q36157711 | Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine |
| Q64060305 | The Antibodiome-Mapping the Humoral Immune Response to HIV |
| Q27000889 | The Antibody Response against HIV-1 |
| Q36276632 | The Breadth and Titer of Maternal HIV-1-Specific Heterologous Neutralizing Antibodies Are Not Associated with a Lower Rate of Mother-to-Child Transmission of HIV-1 |
| Q27680688 | The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies |
| Q52584646 | The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses |
| Q54987756 | The Janus Face of Follicular T Helper Cells in Chronic Viral Infections. |
| Q26797466 | The role of Fc-FcγR interactions in IgG-mediated microbial neutralization |
| Q37547702 | The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques. |
| Q38046109 | Tools to therapeutically harness the human antibody response |
| Q36972591 | Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding |
| Q33854841 | Transplanting supersites of HIV-1 vulnerability |
| Q34991017 | Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope |
| Q34441935 | Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization |
| Q92479131 | Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies |
| Q38764543 | Use of broadly neutralizing antibodies for HIV-1 prevention |
| Q61448102 | VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120 |
| Q33612459 | Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates |
| Q34203163 | Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection |
| Q92883419 | Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins |
| Q27676728 | Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth |
| Q27025177 | Virological features associated with the development of broadly neutralizing antibodies to HIV-1 |
| Q40346802 | Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. |
| Q35641144 | What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure? |
| Q47561102 | What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM. |
| Q33772637 | Which Antibody Functions are Important for an HIV Vaccine? |
| Q39160496 | Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design? |
| Q35192660 | epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals |
Search more.